AR and Beyond: ctDNA Maps Resistance Evolution in mCRPC.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 41996129.
- Also identified by DOI 10.1158/1078-0432.CCR-26-0478.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Longitudinal plasma cfDNA profiling from the phase 3 Alliance A031201 trial revealed divergent resistance trajectories in mCRPC. Rapid progressors harbored non-AR alterations suggesting intrinsic resistance, whereas delayed progressors showed progressive AR amplifications, structural rearrangements and extrachromosomal DNA-associated evolution. These findings support biomarker-guided strategies targeting AR-dependent and AR-independent disease states.